Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 5/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355967 | 0.82 | — | — | |
| SCHEMBL3357439 | 0.79 | — | — | |
| SCHEMBL6106735 | 0.67 | KDM4E (0.43) | TNKSNPSR1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL5827326 | 0.67 | — | — | |
| SCHEMBL14130986 | 0.67 | KDM4E (0.44) | TNKSNPSR1CYP1A2CYP2C19KDM4E | |
| SCHEMBL3960659 | 0.65 | GABRA1 (0.60) | GABRA1GABRB2GABRG2GABRB3GABRA2 | |
| SCHEMBL843296 | 0.65 | MEN1 (0.38) | TNKSNPSR1KDM4ERXFP1SMN1; SMN2 | |
| SCHEMBL11866697 | 0.62 | NPSR1 (0.34) | TNKSNPSR1CYP1A2CYP2C19KDM4E | |
| Hydrochloric Acid SCHEMBL9285560 | 0.61 | GABRA1 (0.39) | GABRA1GABRB2TLR7 | |
| SCHEMBL16101465 | 0.61 | GABRA1 (0.54) | GABRA1GABRB2ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026482-B2 | Process for preparing imidazoquinolinamines | MEDICIS PHARMACEUTICAL CORPORATION | 2006-04-11 | — | — | US | disclosed |
| US-6897314-B2 | Process for preparing imidazoquinolinamines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050096470-A1 | Process for preparing imidazoquinolinamines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-05 | — | — | US | disclosed |
| EP-0912565-B1 | PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES | MINNESOTA MINING & MFG (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20040019213-A1 | Process for preparing imidazoquinolinamines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-6624305-B2 | Reacting a 6H-imidazo(4,5-c) tetrazolo(1,5-a)quinoline with triphenylphosphine and hydrolyzing | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6613902-B2 | Induce biosynthesis of cytokines such as interferons, interleukins, and tumor necrosis factor in humans and in mice. | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-02 | — | — | US | disclosed |
| US-20030153762-A1 | Process for preparing imidazoquinolinamines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-14 | — | — | US | disclosed |
| US-20030130516-A1 | PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-10 | — | — | US | disclosed |
| US-6534654-B2 | Providing a tetrazole(1,5-a)quinolin-5-ol and nitrating the compound to form 4-nitrotetrazole(1,5-a)quinoline-5-ol, sulfonylating at 5-position, reacting with an amine to form a 5-amine derivative, further reducing to form 4,5-daimines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20020188127-A1 | Process for preparing imidazoquinolinamines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-12 | — | — | US | disclosed |
| US-6437131-B1 | REACTING A 6H-IMIDAZO(4,5-C)TETRAZOLO(1,5-A)QUINOLINE WITH TRIPHENYLPHOSPHINE, HYDROLYZING TO FORM 1H-IMIDAZO(4,5-C) QUINOLIN-4-AMINES; INTERMEDIATE IS A 4-NITROTETRAZOLO(1,5-A) QUINOLIN-5-SULFONATE IN THE PR | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-20 | — | — | US | disclosed |
| EP-0912565-A1 | PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048704-A1 | PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019213-A1 | Process for preparing imidazoquinolinamines | VAT1, QARS1, TALDO1 | GABRA1 3641/4885GABRB2 4574/4885TNKS 40/4885 |
| US-20050096470-A1 | Process for preparing imidazoquinolinamines | ITPA, INMT, PIP4K2C | GABRA1 3569/4885GABRB2 4220/4885TNKS 40/4885 |
| US-20020188127-A1 | Process for preparing imidazoquinolinamines | VAT1, QARS1, TALDO1 | GABRA1 3641/4885GABRB2 4574/4885TNKS 40/4885 |
| US-20030130516-A1 | PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES | VAT1, QARS1, TALDO1 | GABRA1 3641/4885GABRB2 4574/4885TNKS 40/4885 |
| US-20030153762-A1 | Process for preparing imidazoquinolinamines | VAT1, QARS1, TALDO1 | GABRA1 3641/4885GABRB2 4574/4885TNKS 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.